<DOC>
	<DOCNO>NCT01840527</DOCNO>
	<brief_summary>This primary purpose study obtain blood sample participant early later stage melanoma ( Stage II/III Stage IV ) . The researcher hope good understand abnormal protein find many melanoma tumor call BRAFV600 mutation . There two separate cohort ( group ) participant study . You place one Groups . Group 1-For participant advance melanoma : Your exist tumor tissue sample compare blood sample give order analyze understand BRAFV600E gene mutation . Group 2-For participant stage II/III melanoma : Following surgery , blood sample collect analyzed . Understanding BRAFV600E gene mutation melanoma help researcher well understand disease , help plan treatment option people melanoma stag future .</brief_summary>
	<brief_title>Utility Novel BRAF Test Melanoma</brief_title>
	<detailed_description>There extra clinic visit study . These research blood sample draw time regularly schedule blood draw part standard care melanoma . About 2 4 teaspoon blood draw research sample . Depending group , either one time blood draw ongoing blood work 1-2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Biopsy proven advance ( unresectable stage IIIC stage IV ) high risk ( stage II stage III ) malignant melanoma History different malignancy except follow circumstance : diseasefree least 2 year deem investigator low risk recurrence ; nonmetastatic prostate cancer , cervical cancer situ basal cell squamous cell carcinoma Known history different BRAF mutant malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Biomarker</keyword>
	<keyword>BRAF</keyword>
	<keyword>blood-based</keyword>
</DOC>